Fructose-coated Angstrom silver inhibits osteosarcoma growth and metastasis via promoting ROS-dependent apoptosis through the alteration of glucose metabolism by inhibiting PDK
Xiong-Ke Hu,Shan -Shan Rao,Yi-Juan Tan,Hao Yin,Ming-Jie Luo,Zhen-Xing Wang,Jin-Hua Zhou,Chun-Gu Hong,Zhong-Wei Luo,Wei Du,Ben Wu,Zi-Qi Yan,Ze-Hui He,Liu Zheng-Zhao,Jia Cao,Yang Wang,Wei-Yi Situ,Hao-Ming Liu,Jie Huang,Yi-Yi Wang,Kun Xia,Yu-Xuan Qian,Yan Zhang,Tao Yue,Yi-Wei Liu,Hong-Qi Zhang,Si -Yuan Tang,Chun-Yuan Chen,Hui Xe
DOI: https://doi.org/10.7150/thno.45858
IF: 11.6
2020-01-01
Theranostics
Abstract:Osteosarcoma is a common malignant bone cancer easily to metastasize. Much safer and more efficient strategies are still needed to suppress osteosarcoma growth and lung metastasis. We recently presented a pure physical method to fabricate Angstrom-scale silver particles (AgAPs) and determined the anti-tumor efficacy of fructose-coated AgAPs (F-AgAPs) against lung and pancreatic cancer. Our study utilized an optimized method to obtain smaller F-AgAPs and aimed to assess whether F-AgAPs can be used as an efficient and safe agent for osteosarcoma therapy. We also investigated whether the induction of apoptosis by altering glucose metabolic phenotype contributes to the F-AgAPs-induced anti-osteosarcoma effects. Methods: A modified method was developed to prepare smaller F-AgAPs. The anti-tumor, anti-metastatic and pro-survival efficacy of F-AgAPs and their toxicities on healthy tissues were compared with that of cisplatin (a first-line chemotherapeutic drug for osteosarcoma therapy) in subcutaneous or orthotopic osteosarcoma-bearing nude mice. The pharmacokinetics, biodistribution and excretion of F-AgAPs were evaluated by testing the levels of silver in serum, tissues, urine and feces of mice. A series of assays in vitro were conducted to assess whether the induction of apoptosis mediates the killing effects of F-AgAPs on osteosarcoma cells and whether the alteration of glucose metabolic phenotype contributes to F-AgAPs-induced apoptosis. Results: The newly obtained F-AgAPs (9.38 A 4.11 nm) had good stability in different biological media or aqueous solutions and were more effective than cisplatin in inhibiting tumor growth, improving survival, attenuating osteolysis and preventing lung metastasis in osteosarcoma-bearing nude mice after intravenous injection, but were well tolerated in normal tissues. One week after injection, about 68% of F-AgAPs were excreted through feces. F-AgAPs induced reactive oxygen species (ROS)-dependent apoptosis of osteosarcoma cells but not normal cells, owing to their ability to selectively shift glucose metabolism of osteosarcoma cells from glycolysis to mitochondrial oxidation by inhibiting pyruvate dehydrogenase kinase (PDK). Conclusion: Our study suggests the promising prospect of F-AgAPs as a powerful selective anticancer agent for osteosarcoma therapy.